Neurvati Neurosciences/GRIN Therapeutics issued a press release announcing that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to radiprodil, the company’s investigational, potent negative allosteric modulator selectively targeting the GluN2B (or NR2B) subunit of the N-methyl-D-aspartate receptor ), for the treatment of GRIN-related neurodevelopmental disorder (NDD). PRIME designation is granted by the EMA in recognition of priority medicines that have demonstrated the potential to target an unmet need to a significant extent. PRIME provides enhanced support for the development of therapeutic candidates in order to help optimize development plans and speed up the evaluation process. You can find the press release here: https://lnkd.in/dWanJnBs... #grigenedisorders #gria #grid #grik #grin
